Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Combined With Radiotherapy in Resected Stage IIIA-N2 EGFR-Mutant NSCLC
NCT03381430Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Primary endpoint: Disease Free Survival at 3 years. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03381430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381430.